News
Alpha-1 Foundation sees Grifols purchase of Talecris as "great opportunity to expand productive collaboration"
MIAMI, FL – The Alpha-1 Foundation sees the acquisition of Talecris Biotherapeutics by Grifols of Spain as “a great opportunity to expand on a productive collaboration,” Foundation President and CEO John Walsh said today.
The U.S. Federal Trade Commission today approved the Grifols purchase of Talecris Biotherapeutics, the manufacturer of Prolastin-C augmentation therapy for Alpha-1 Antitrypsin Deficiency.
“The Grifols family has been a leader in producing safe, effective plasma therapies,” Walsh said. “Under Victor Grifols Roura, we expect that family culture to expand in the United States. The Alpha-1 community has always been a family, and we look forward to a complementary blending of two family traditions.”
Victor Grifols Roura, president and CEO of Grifols, runs the company founded by his grandfather in 1940. When Grifols Roura was presented with the Global Business Leader Award this year from the American Chamber of Commerce in Spain, Walsh commented, “he has built a corporate culture that embraces the needs of individuals affected by disorders like Alpha-1 requiring plasma-derived therapies.”
Walsh noted that Grifols has committed to maintaining Talecris’s Prolastin Direct program.
Added Walsh: “We have enjoyed a great working relationship with the Talecris leadership. The Foundation recognized Talecris Chairman and CEO Lawrence Stern with a Distinguished Service Award at our Celebration of Life event this spring.”
